CC
ORIC icon

Commodore Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Commodore Capital’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,000,000
Closed -$11.2M – 36
2025
Q1 		$11.2M Hold
2,000,000
– – 0.82% 24
2024
Q4 		$16.1M Hold
2,000,000
– – 1.18% 22
2024
Q3 		$20.5M Hold
2,000,000
– – 1.28% 24
2024
Q2 		$14.1M Hold
2,000,000
– – 0.97% 26
2024
Q1 		$27.5M Buy
+2,000,000
New +$23.8M 1.84% 20

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Commodore Capital's ORIC Position: Q2 2025 in Review

Commodore Capital sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 2,000,000 shares — an estimated $11.2M sold.

Commodore Capital first reported a position in ORIC in Q1 2024 and held it in 5 quarters. The position peaked at $27.5M in Q1 2024. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

  • Commodore Capital reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Commodore Capital sold 2,000,000 Oric Pharmaceuticals shares in Q2 2025, an estimated $11.2M.
  • Commodore Capital first reported a position in Oric Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Commodore Capital's Oric Pharmaceuticals position peaked at $27.5M in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on Commodore Capital's 13F filing for Q2 2025, filed 14 Aug 2025.